Could a probiotic boost a cancer drug? new trial tests the combo
NCT ID NCT07578025
First seen May 19, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This phase 2 trial tests whether adding a probiotic capsule (MO-03) to the drug zanzalintinib can help treat metastatic kidney cancer that has worsened after immunotherapy. About 34 adults with advanced clear cell renal cell carcinoma will receive both treatments. The goal is to see if the combination shrinks tumors or slows cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanzalintinib (a targeted drug) and MO-03 (a probiotic capsule)
What this could lead to
If it works, this could offer a new treatment option for people with advanced kidney cancer that has stopped responding to immunotherapy.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. The combination may not work better than existing treatments, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.